Abstract Mutations in the SLC26A4 gene at the DFNB4 locus are responsible for Pendred syndrome and nonsyndromic hereditary hearing loss (DFNB4). This study included 80 nuclear families with two or more siblings segregating presumed autosomal recessive hearing loss. All deaf persons tested negative for mutations in GJB2 at the DFNB1 locus and were, therefore, screened for autozygosity by descent (ABD) using short tandem repeat polymorphisms (STRPs) that flanked SLC26A4. In 12 families, homozygosity for STRPs suggested possible ABD in this genomic region. Affected individuals in five families had a positive perchlorate discharge test. Sequence analysis of SLC26A4 identified ten mutations in eight families (T420I, 1197delT, G334V, R409H, T721M, R79X, S448L, L597S, 965insA and L445W), of which, four are novel (T420I, G334V, 965insA and R79X). These results imply that Pendred syndrome is the most prevalent form of syndromic hereditary hearing loss in Iran.
Introduction
Inherited deafness is common, occurring approximately once in every 2,000 live births. The severity of this loss can vary from mild to profound [4, 7] and approaches to its investigation are varied. In many countries around the world, mutations in GJB2, a gene at the DFNB1 locus, are the most common cause of autosomal recessive hearing loss (ARHL) and the mutation screening of this gene is recommended as an early diagnostic test.
Several studies have shown that mutations in SLC26A4 are the second most common cause of ARHL [8] . This gene encodes a chloride-iodide transporter and is associated with both syndromic hearing loss, Pendred syndrome (PDS;(enlargement of the vestibular aqueduct, EVA) [5] . The encoded protein, pendrin [9] , is composed of 780 amino acids and has a molecular weight of 86 kDa. It is expressed in the thyroid, inner ear and kidney.
To date, more than 90 mutations in SLC26A4 have been described in patients with PDS and DFNB4 [1, 10] . The phenotype associated with these mutations can vary. At one extreme, there is congenital sensorineural hearing loss, thyroid dysfunction as manifested by goiter with an abnormal perchlorate discharge test, and bony abnormalities of the inner ear, typically either Mondini dysplasia or EVA, as resolved by temporal bone computed tomography. However, the presence of thyroid dysfunction is most variable, and at the other end of the phenotypic spectrum, there is congenital sensorineural hearing loss associated only with EVA.
The genetic basis for the observed phenotypic variability has not been definitively resolved. There is evidence for a functional difference between some SLC26A4 mutations segregating with PDS versus DFNB4; however, other mutations are associated with either phenotype, suggesting that other genetic or environmental factors also contribute to the final phenotype. In this study, we sought to determine the prevalence of SLC26A4 mutations in families with ARHL among the Iranian deaf population.
Materials and methods

Families
Included in this study were 80 unrelated families of consanguineous parentage segregating presumed ARHL, as evidenced by the presence of at least two deaf siblings in each nuclear family. Informed consent was obtained from all persons interested in participating in this study. All of the affected persons had severe-to-profound deafness, as determined by audiometric testing, and were negative for GJB2 and GJB6 mutations. Evidence of thyroid dysfunction was assessed by determining the thyroid size using Tc-99m scanning and thyroid function based on the serum levels of TSH (normal, 0.3-3.5 mIU/L), T3 RU (normal, 25-35%), T4 RIA (normal, 4.0-13.0 ug/dl), FTI (normal, 1.1-4.5), T3RIA (normal, 80-200 ng/dl), free T3 (normal, 1.6-3.7 pg/ml), free T4 (normal, 0.8-2.2 ng/dl), h Tg (normal, 2-50 ng/ml), anti-Tg (normal, 0-150 IU/ml) and perchlorate discharge (abnormal or positive result, release of more than 20% of radioactive iodide). The possibility of mutations in SLC26A4 was evaluated by screening for autozygosity by descent (ABD) using short tandem repeat polymorphisms (STRPs) that flank SLC26A4. Approval for this study came from the ethical committees at the University of Social Welfare and Rehabilitation Sciences and the University of Iowa.
Mutation screening
Each person donated approximately 10 cc of whole blood, from which DNA was extracted according to standard protocols. STRPs D7S496, D7S523, D7S501 and D7S1817 were resolved in the affected persons from each family. The amplification conditions were 95°C for 5 min, followed by 30 cycles each of 94°C for 40 s, 57°C for 30 s and 72°C for 40 s. Polymerase chain reaction (PCR) products were visualised using silver nitrate staining of an 8% acrylamide 4 Novel mutation 5 NL = normal gel after separating amplimers for 2.5 h at 200 V. If STRP scoring was consistent with ABD, the mutation screening of SLC26A4 was completed. All 21 exons of this gene were amplified by PCR, as described by Coyle et al. [2] , and were bidirectionally sequenced using an automated sequencing system (ABI 3130XL Sequencer).
Results
As shown in Table 1 , of the 80 families included in this study, presumed ABD to the genomic region that includes SLC26A4 based on STRP analysis was present in 12. By the mutation screening of SLC26A4, we were able to identify 10 mutations (T420I, 1197delT, G334V, R409H, T721M, R79X, S448L, L597S, 965insA and L445W) in eight of these families. In each of these eight families, mutations were identified on both alleles. We found no mutations in SLC26A4 in four families. Goitrous changes of the thyroid gland were present in all 12 families and in three, there was evidence of hypothyroidism. The perchlorate discharge test was positive in persons from five different families, with loss of between 23 and 63% of the unincorporated iodide 2 h after the administration of 1 g KClO 4 . Affected persons in each of these families also had EVA. In aggregate, in the eight families segregating SLC26A4 mutations, the type of goiter and degree of thyroid dysfunction varied. In only one family, with two affected members (T721M homozygotes), was the PDT markedly positive (>50%).
Discussion
After GJB2, mutations in SLC26A4 are the most common cause of ARHL. They account for approximately 5% of all prelingual deafness in East Asia and 5% of recessive deafness in South Asia [6] . In this study, we identified a spectrum of mutations in SLC26A4 in Iranian families segregating ARHL. The mutations were associated with a PDS phenotype. Although 12 of 80 families were found to have ABD consistent with linkage to the SLC26A4 genomic region, we were able to detect mutations in only eight families. In these families, we identified ten different mutations, four of which are novel (T420I, R79X, G334V and 965insA). We were unable to find mutations in four families, which is consistent with the finding of Yang et al., showing that the EVA phenotype is genetically complex [11] .
We did not find any correlation between the severity of hearing loss and the type of mutation in SLC26A4. In our patients, EVA was the only temporal bone anomaly we observed, suggesting that EVA may be more common that Mondini dysplasia in persons with PDS. Thyroid evaluation revealed some degree of post-puberty goiter, consistent with most studies, which have shown that the majority of patients with PDS develop goitrous changes around puberty. Thyroid goiter is not synonymous with hypothyroidism, and the prevalence of hypothyroidism in this study is similar to that reported in other populations [3] . Like others, we also observed intra-and inter-familial variability in thyroid manifestations.
Our results identify PDS as the most prevalent form of syndromic hereditary hearing loss in Iran. It is, typically, difficult to differentiate from non-syndromic hearing loss in children. For that reason, we would recommend the mutation screening of SLC26A4 in persons with severe-toprofound congenital hearing loss who have EVA, as resolved by temporal bone computed tomography.
